

# Total synthesis of pachastrissamine (jaspine B) enantiomers from D-glucose

C. V. Ramana,\* Awadut G. Giri, Sharad B. Suryawanshi and Rajesh G. Gonnade

National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India

Received 7 August 2006; revised 1 November 2006; accepted 8 November 2006

Available online 28 November 2006


**Abstract**—Synthesis of both enantiomers of pachastrissamine is described from a common chiral template. The stereoselective construction of the central tetrahydrofuran units was based on the pseudodesymmetrization of a pentodialdo-1,4-furanose derivative taking advantage of the latent symmetry present.

© 2006 Published by Elsevier Ltd.

Pachastrissamine (**1**, Fig. 1), isolated and characterized by Higa and co-workers in 2002 from the Okinawa marine sponge *Pachastrissa* sp. (family Calthropellidae) is a novel anhydrophytosphingosine with important bioactivity.<sup>1</sup> It was later (in 2003) isolated from another marine sponge, genus *Jaspis* by Debitus and co-workers and named as jaspine B.<sup>2</sup> The structure of **1** and the all-cis geometry of the THF ring was assigned by spectroscopy, largely NMR, and the (2*S*,3*S*,4*S*) configuration of the ring carbon atoms was determined on the basis of (*S*)- and (*R*)-MTPA derivatization on the N-monoacetylated pachastrissamine. This was reported to exhibit

promising cytotoxic activity in the submicromolar range against P388, A549, HT29, and MEL28 (IC<sub>50</sub> = 0.001 µg/mL) cell lines. Its simple structure and this promising biological activity have stimulated substantial synthetic work, culminating in several total syntheses.<sup>3–7</sup> In this letter we wish to report a chiral pool synthesis of both **1** and its antipode **2** starting from a single chiron.

As shown in Figure 1, our intended strategy exploited the pseudosymmetry present in pentodialdo-1,4-furanose **9**<sup>8</sup> to derive enantiomeric azidoalkynes **3** and **4**, which upon alkylation and hydrogenation should result



**Figure 1.** The key pseudodesymmetrization strategy for (+)- and (-)-pachastrissamine.

**Keywords:** Chiron approach; Pachastrissamine/jaspine B; Pentodialdo-1,4-furanose; Ohira–Bestmann reaction; Ring isomerization.

\* Corresponding author. Tel.: +91 20 25902577; fax: +91 20 25902629; e-mail: [vr.chepuri@ncl.res.in](mailto:vr.chepuri@ncl.res.in)


in the synthesis of **1** and **2**, respectively.<sup>9</sup> We anticipated that the two enantiomeric furan systems **5** and **6** could be fashioned efficiently by employing selective Ohira–Bestmann alkylation at either end of **9**. The Ohira–Bestmann alkylation at C(5) is a direct proposition, whereas for the Ohira–Bestmann alkylation at C(1), we were interested in the acid mediated ring isomerization of **8**.

Prior to the discussion on the synthesis of enantiomeric alkynols **5** and **6**, it is pertinent to mention that while our work was in progress furanoaldehyde **7** was prepared and used by Linhardt and co-workers<sup>5</sup> for the synthesis of natural pachastrissamine (**1**). The synthesis of alkynol **5** started with reduction of the easily available dialdofuranose **9** (prepared from D-glucose following the literature procedure, Scheme 1) with NaBH<sub>4</sub>.<sup>10</sup> Tosylation of **10** using *p*-TsCl in pyridine followed by acid mediated acetone deprotection with concomitant 2,5-ring closure gave dimethylacetal **11** in a good yield. The following acetal hydrolysis reaction proceeded with 2 N sulfuric acid in acetic acid and the resulting aldehyde **7** was subjected to Ohira–Bestmann alkylation under standard conditions.<sup>11</sup>


Alkynol **6** was prepared in two steps from **9** by first subjecting it to the Ohira–Bestmann alkylation and then

reductive deketalization<sup>12</sup> of the resulting alkynol **12**<sup>13</sup> using excess triethylsilane in the presence of BF<sub>3</sub>·Et<sub>2</sub>O. The spectral data of **6** were comparable with its antipode **5**.<sup>14</sup>


Once we had easy access to enantiomeric alkynols **5** and **6**, the stage was set for the synthesis of the mirror isomers of pachastrissamine. Thus, alkynols **5** and **6** were transformed to the corresponding azidoalkynes **3** and **4** by treatment with Tf<sub>2</sub>O in pyridine followed by reacting the intermediate triflates with LiN<sub>3</sub> in DMF. The spectral and analytical data of compounds **3** and **4** were in agreement with the proposed structures.<sup>15</sup> After examining a set of bases and reaction conditions, we concluded that the alkylation of azidoalkynes **3**, **4** with 1-bromododecane was facile using *n*-BuLi in THF–HMPA and the alkylated products **13** and **14** were obtained in 61% and 57% yields, respectively.<sup>16</sup> Hydrogenolysis of **13** and **14** was effected by refluxing in methanol in the presence of ammonium formate and cat. 10% Pd/C. The requisite pachastrissamine enantiomers were characterized either after chromatographic purification or as their diacetates **15** and **16**, respectively (Scheme 2). The spectral and analytical data of the **1** and its diacetate **15**<sup>17</sup> were in agreement with the reported values and the structure of **15** was further established by single crystal X-ray analysis (Fig. 2).<sup>18–20</sup>



**Scheme 1.** Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 0 °C, 2 h; (b) *p*-TsCl, pyridine, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 5 h; (c) PTSA, methanol, reflux, 6 h; (d) 2 N, H<sub>2</sub>SO<sub>4</sub>, 50% AcOH, 9 °C, 2 h; (e) (MeO)<sub>2</sub>P(=O)C(=N<sub>2</sub>)COCH<sub>3</sub>, methanol, K<sub>2</sub>CO<sub>3</sub>, rt, 7–9 h; (f) BF<sub>3</sub>·Et<sub>2</sub>O, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, –20 °C – rt, 6 h.



**Figure 2.** ORTEP structure of compound **15**.



**Scheme 2.** Reagents and conditions: (a) (i)  $\text{TiF}_2\text{O}$ , pyridine,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 6 h; (ii)  $\text{LiN}_3$ , DMF, rt, 12 h; (b)  $n\text{-BuLi}$ , THF:HMPA (7:1),  $\text{C}_{12}\text{H}_{25}\text{Br}$ ,  $-78$  to  $-40^\circ\text{C}$ , 1 h; (c) 10% Pd/C, ammonium formate, MeOH, reflux, 10 h; (d)  $\text{Ac}_2\text{O}$ ,  $\text{Et}_3\text{N}$ , DMAP,  $\text{CH}_2\text{Cl}_2$ , rt, 6 h.

In summary, we have reported a simple chiral pool strategy for the synthesis of both enantiomers of pachastrissamine starting with  $\text{D}$ -glucose. The synthesis is sufficiently flexible to allow substitution or variation in the length of the side chain to synthesize analogues.

### Acknowledgements

We thank Mukund K. Gurjar for encouragement and the Department of Science and Technology (New Delhi), for the project grant (SR/FTP/CSA-02/2002) under the 'Fast Track Proposals for Young Scientists'. AGG thanks UGC (New Delhi), S.B.S. thanks CSIR (New Delhi), for the financial assistance in the form of research fellowships.

### References and notes

- Kuroda, I.; Musman, M.; Ohtani, I. I.; Ichiba, T.; Tanaka, J.; Gravalos, D. G.; Higa, T. *J. Nat. Prod.* **2002**, *65*, 1505–1506.
- Ledroit, V.; Debitus, C.; Lavaud, C.; Massiot, G. *Tetrahedron Lett.* **2003**, *44*, 225–228.
- Sudhakar, N.; Kumar, A. R.; Prabhakar, A.; Jagadeesh, B.; Rao, B. V. *Tetrahedron Lett.* **2005**, *46*, 325–327.
- Bhaket, P.; Morris, K.; Stauffer, C. S.; Datta, A. *Org. Lett.* **2005**, *7*, 875–876.
- Du, Y.; Liu, J.; Linhardt, R. J. *J. Org. Chem.* **2006**, *71*, 1251–1253.
- Van Tien Berg, R. J. B. H. N.; Boltje, T. J.; Verhagen, C. P.; Litjens, R. E. J. N.; Van Der Marel, G. A.; Overkleef, H. S. *J. Org. Chem.* **2006**, *71*, 836–839.
- Ribes, C.; Falomir, E.; Carda, M.; Marco, J. A. *Tetrahedron* **2006**, *62*, 5421–5425.
- (a) Defaye, J.; Ratovelomanana, V. *Carbohydr. Res.* **1971**, *17*, 57–65; (b) Defaye, J.; Horton, D.; Muesser, M. *Carbohydr. Res.* **1971**, *20*, 305–318; (c) Yu, H.-W.; Zhang, H.-Y.; Yang, Z.-J.; Min, J.-M.; Ma, L.-T.; Zhang, L.-H. *Pure Appl. Chem.* **1998**, *70*, 435–438.
- For earlier pseudodesymmetrization approaches employing sugar chiroins, see: (a) Hoffmann, H. M. R.; Dunkel, R.; Mentzel, M.; Reuter, H.; Stark, C. B. W. *Chem. Eur. J.* **2001**, *7*, 4772–4789; (b) Boulineau, F. P.; Wei, A. J. *Org. Lett.* **2004**, *6*, 119–121; (c) Boulineau, F. P.; Wei, A. J. *Org. Chem.* **2004**, *69*, 3391–3399.
- (a) Horton, D.; Swanson, F. O. *Carbohydr. Res.* **1970**, *14*, 159–171; (b) Patil, N. T.; John, S.; Sabharwal, S. G.; Dhavale, D. D. *Bioorg. Med. Chem.* **2002**, *10*, 2155–2160.
- (a) Ohira, S. *Synth. Commun.* **1989**, *19*, 561–564; (b) Roth, G. J.; Liepold, B.; Müller, S. G.; Bestmann, H. J. *Synlett* **1996**, 521–522.
- (a) Bennek, J. A.; Gray, G. R. *J. Org. Chem.* **1987**, *52*, 892–897; (b) Murty, K. V. S. N.; Vasella, A. *Helv. Chim. Acta* **2001**, *84*, 939–963.
- Tronchet, J. M. J.; Gonzalez, A.; Zumwald, J. B. *Helv. Chim. Acta* **1974**, *57*, 1505–1510.
- Spectral data of 5*.  $[\alpha]_{\text{D}}^{25} -57.9$  (c 1,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ )  $\nu$ : 3403, 3290, 3065, 2942, 2120, 1598, 1496, 1218, 1069, 754, 698,  $666\text{ cm}^{-1}$ .  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ : 2.15 (br s, 1H), 2.57 (d,  $J = 2.3$  Hz, 1H), 3.67 (dd,  $J = 2.2, 9.8$  Hz, 1H), 3.91 (dd,  $J = 2.3, 4.7$  Hz, 1H), 4.18 (dd,  $J = 4.7, 9.8$  Hz, 1H), 4.32–4.34 (dt,  $J = 2.3, 4.7$  Hz, 1H), 4.64 (d,  $J = 11.9$  Hz, 1H), 4.77 (dd,  $J = 2.2, 4.7$  Hz, 1H), 4.78 (d,  $J = 11.9$  Hz, 1H), 7.27–7.38 (m, 5H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$ : 70.6 (d), 72.7 (t), 73.1 (t), 75.5 (d), 76.4 (d), 78.9 (s), 84.9 (d), 127.8 (d), 127.9 (d), 128.5 (d), 137.5 (s) ppm. ESI-MS:  $m/z$  219.1 (23%,  $[\text{M}+1]^+$ ), 236.2 (38%,  $[\text{M}+\text{NH}_4]^+$ ), 241.2 (100%,  $[\text{M}+\text{Na}]^+$ ), 257.1 (18%,  $[\text{M}+\text{K}]^+$ ). Anal. calcd for  $\text{C}_{13}\text{H}_{14}\text{O}_3$ : C, 71.54; H, 6.47. Found: C, 71.44; H, 6.59. *Spectral data of 6*.  $[\alpha]_{\text{D}}^{25} 56$  (c 0.9,  $\text{CHCl}_3$ ). ESI-MS:  $m/z$  241.3 (100%,  $[\text{M}+\text{Na}]^+$ ), 257.3 (24%,  $[\text{M}+\text{K}]^+$ ). Anal. calcd for  $\text{C}_{13}\text{H}_{14}\text{O}_3$ : C, 71.54; H, 6.47. Found: C, 71.49; H, 6.39.
- Spectral data of 3*.  $[\alpha]_{\text{D}}^{25} -69$  (c 1.3,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ )  $\nu$ : 3304, 3020, 2125, 2110, 1603, 1585, 1216, 759, 698,  $638\text{ cm}^{-1}$ .  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ : 2.64 (d,  $J = 2.3$  Hz, 1H), 3.92–4.04 (m, 3H), 4.16 (br dd,  $J = 5.0, 6.1$  Hz, 1H), 4.71 (dd,  $J = 2.3, 6.1$  Hz, 1H), 4.74 (d,  $J = 11.8$  Hz, 1H), 4.83 (d,  $J = 11.8$  Hz, 1H), 7.31–7.46 (m, 5H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$ : 59.9 (d), 69.4 (t), 69.7 (d), 73.2 (t), 76.9 (d), 78.8 (s) 79.4 (d), 127.9 (d), 128.0 (d), 128.5 (d), 137.0 (s). Anal. calcd for  $\text{C}_{13}\text{H}_{13}\text{N}_3\text{O}_2$ : C, 64.19; H, 5.39, N, 17.27. Found: C, 64.29; H, 5.21, N, 17.18. *Spectral data of 4*.  $[\alpha]_{\text{D}}^{25} 70.1$  (c 1.3,  $\text{CHCl}_3$ ). ESI-MS:  $m/z$  267.3 (27%), 283.4 (40%,  $[\text{M}+\text{K}]^+$ ). Anal. calcd for  $\text{C}_{13}\text{H}_{13}\text{N}_3\text{O}_2$ : C, 64.19; H, 5.39, N, 17.27. Found: C, 64.01; H, 5.61, N, 17.24.
- Weaving, R.; Roulland, E.; Monneret, C.; Florent, J.-C. *Tetrahedron Lett.* **2003**, *44*, 2579–2581.
- Spectral data of 15*. Mp:  $110^\circ\text{C}$ ;  $[\alpha]_{\text{D}}^{25} -34.6$  (c 1,  $\text{CHCl}_3$ ), lit.<sup>7</sup>  $[\alpha]_{\text{D}}^{25} -28.4$  (c 1,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ )  $\nu$ : 3019, 2927, 2855, 1743, 1676, 1550, 1467, 1374, 1215, 1049,  $757\text{ cm}^{-1}$ .  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ : 0.86 (t,  $J = 6.8$  Hz, 3H), 1.23 (br s, 24H), 1.40–1.48 (m, 2H), 1.97 (s, 3H), 2.15 (s, 3H), 3.58 (dd,  $J = 7.9, 8.6$  Hz, 1H), 3.85–3.93 (m, 1H), 4.06

- (dd,  $J = 8.1, 8.6$  Hz, 1H), 4.80 (dq,  $J = 5.4, 8.0$  Hz, 1H), 5.37 (dd,  $J = 3.4, 5.5$  Hz, 1H), 5.61 (d,  $J = 8.2$  Hz, 1H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$ : 14.1 (q), 20.6 (q), 22.6 (t) 23.1 (q), 26.0 (t), 29.3 (2t), 29.4 (t), 29.5 (2t), 29.6 (2t), 31.9 (t), 51.3 (d), 69.9 (t), 73.5 (d), 81.20 (d). ESI-MS:  $m/z$  384.2 (82%,  $[\text{M}+1]^+$ ), 406.3 (100%,  $[\text{M}+\text{Na}]^+$ ). Spectral data of **16**. Mp: 108 °C;  $[\alpha]_{\text{D}}^{25}$  29 ( $c$  1,  $\text{CHCl}_3$ ). ESI-MS:  $m/z$  384.4 (23%,  $[\text{M}+1]^+$ ), 406 (100%,  $[\text{M}+\text{Na}]^+$ ), 422.3 (20%  $[\text{M}+\text{K}]^+$ ).
18. X-ray intensity data was collected on a Bruker SMART APEX CCD diffractometer with graphite-monochromatized ( $\text{Mo K}\alpha = 0.71073 \text{ \AA}$ ) radiation at room temperature. All the data were corrected for Lorentzian, polarization, and absorption effects using Bruker's SAINT and SADABS programs. SHELX-97 (G.M. Sheldrick, SHELX-97 program for crystal structure solution and refinement, University of Gottingen, Germany, 1997)<sup>19</sup> was used for structure solution and full-matrix least-squares refinement on  $F^2$ . Hydrogen atoms were included in the refinement as per the riding model.
19. Sheldrick, G. M. SHELX-97 Program for Crystal Structure Solution and Refinement; University of Gottingen: Germany, 1997.
20. The crystallographic data has been deposited with the Cambridge Crystallographic Data Centre as deposition No. CCDC 617243 (**15**). Copies of the data can be obtained, free of charge, on application to the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (1223) 336033; e-mail: deposit@ccdc.cam.ac.uk].